摘要
目的：检测卵巢肿瘤组织中多药耐药基因的表达并探讨其临床意义。方法：采用ＲＮＡ多聚酶链反应（ＲＴ－ＰＣＲ）方法，对３５例卵巢恶性肿瘤，２０例卵巢良性肿瘤和１７例正常卵巢组织标本进行多药耐药基因（ＭＤＲ１）表达的测定。结果：（１）卵巢恶性肿瘤组织中ＭＤＲ１表达阳性率为５７．１４％，而卵巢良性肿瘤和正常卵巢组织中则无一例ＭＤＲ１表达阳性。（２）卵巢恶性肿瘤中，初治者和复发者的ＭＤＲ１表达阳性率分别为４０．９１％和８４．６２％。（３）恶性肿瘤的癌旁、癌灶和转移灶组织中的ＭＤＲ１表达阳性率分别为１１．８％、５２．９％和７０．６％。（４）ＭＤＲ１表达阳性的恶性肿瘤患者对化疗的有效率低于ＭＤＲ１表达阴性者。（５）不同病理类型和临床分期的恶性肿瘤组织中的ＭＤＲ１表达阳性率相比较，差异无显著性。结论：卵巢恶性肿瘤组织中ＭＤＲ１阳性表达与其临床耐药有关。
Objectives:Tomeasurethemultidrugresistancegene(MDR1)messengerRNA(mRNA)contentofovariancarcinomaandtoinvestigatetheclinicalsignificanceofMDR1expressioninovariancarcinoma.Methods:Asensitiveassaybasedonthepolymerasechainreaction(PCR)wasusedtomeasureMDR1mRNAinbiopsysamplesof35ovariancarcinoma,20ovarianbenigntumorsand17normalcontrols.Pathologicaldiagnosiswasmadefromthesesamples.Results:(1)Theex-pressionrateofMDR1inovariancarcinomaswas57.1%,buttherewasnoexpressioninbenignovar-iantumorsandinthenormalcontrols.(2)40.9%ofpatientsgivenprimarytreatmentsand84.6%ofpatientspreviouslytreatedbutwithrelapseshadoverexpressionofMDR1gene.(3)ThepositiveexpressionrateofMDR1incancerlesion,itsadjacentsitesandmetastasiswas52.9%,11.8%and70.6%respectively.(4)Theresponseratetochemotherapywaslowerinpatientswithoverexpres-sionofMDR1genethaninpatientswithoutsuchexpression.(5)Nosignificantcorrelationwasob-servedwhenthepositiverateofexpressionofMDR1incancertissueswasanalyzedagainstclinicalstagesandpathologicaltypes.Conclusions:TheoverexpressionofMDR1wascorrelatedwithac-quireddrug-resistanceinpatientswithovariancaracinoma.MeasurementoftheexpressionofMDR1inapatients′stumormaybeofvalueclinicalyindetectingdrug-sensitivityandinpredictingprogno-sis.
出处
《中华妇产科杂志》
CAS
CSCD
北大核心
1996年第11期652-655,共4页
Chinese Journal of Obstetrics and Gynecology
关键词
卵巢肿瘤
抗药性
基因表达
OvarianneoplasmsDrugresistance,multipleGeneexpression
